Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: Functional receptor-binding and in vivo electrophysiological studies

Psychopharmacology

Volumn 190, Issue 3, 2007, Pages 373-382

  Stark, Arlene D ^a   Jordan, Shaun ^b   Allers, Kelly A ^c   Bertekap, Robert L ^a   Chen, Ruoyan ^b   Mistry Kannan, Tanaz ^a   Molski, Thaddeus F ^a   Yocca, Frank D ^a   Sharp, Trevor ^c   Kikuchi, Tetsuro ^d   Burris, Kevin D ^e  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e Palatin Technologies   (United States)

Author keywords

Antagonist; Aripiprazole; Dopamine; Partial agonist; Schizophrenia; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ARIPIPRAZOLE; BUSPIRONE; CALCIUM ION; CLOZAPINE; FLUOXETINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; KETANSERIN; MESULERGINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; PARTIAL AGONIST; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN TRANSPORTER; ZIPRASIDONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROPHYSIOLOGY; HIPPOCAMPUS; HUMANS; MALE; NEURONS; PIPERAZINES; QUINOLONES; RADIOLIGAND ASSAY; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33846496203     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0621-y     Document Type: Article

References (38)

1. Andrade R (1998) Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Ann N Y Acad Sci 861:190-203
2. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A (2005) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D(2) antagonist and 5-HT(1A) agonist properties. Neuropsychopharmacology 31:1869-1879
3. Blier P, de Montigny C (1987) Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1:470-480
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
6. Ceci A, Baschirotto A, Borsini F (1994) The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 33:709-713
7. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
8. 1A receptor activation. Brain Res 1043(1-2):32-41
9. Davies M, Sheffler D, Roth B (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10:317-336
10. Hajos M, Hajos-Korcsok E, Sharp T (1999) Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 126:1741-1750
11. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18:335-343
12. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137-143
13. Ivins KJ, Molinoff PB (1990) Serotonin-2 receptors coupled to phosphoinositide hydrolysis in a clonal cell line. Mol Pharmacol 37:622-630
14. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 441:137-140
15. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
16. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651-1658
17. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336
18. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117
19. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136
20. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T (2002) Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 5:S176
21. Meller E, Goldstein M, Bohmaker K (1990) Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37:231-237
22. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S
23. Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295:853-861
24. Miyamoto S, Duncan GE, Mailman RB, Lieberman JA (2000) Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2:25-39
25. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S] GTPgammaS binding study. Eur J Pharmacol 355:245-256
26. O'Neill C, Cowburn RF, Wiehager B, Alafuzoff I, Winblad B, Fowler CJ (1991) Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease. Neurosci Lett 133:15-19
27. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA (2005) Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66:1326-1330
28. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690
29. Roth BL, Meltzer HY (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, NY, pp 1215-1227
30. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 51:660-672
31. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
32. Simon JS, Nemeroff CB (2005) Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 66:1216-1220
33. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384
34. Van der Maelen C, Matheson G, Wilderman R, Patterson L (1986) Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 129:123-130
35. Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311-321
36. Wohlpart KL, Molinoff PB (1998) Characterization of 5-HT- and ionomycin-stimulated changes in levels of intracellular calcium and PI hydrolysis in P11 cells. Ann N Y Acad Sci 861:240-241
37. Yocca FD, Hyslop DK, Smith DW, Maayani S (1987) BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes. Eur J Pharmacol 137:293-294
38. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521-529